| Ytd | -0.28% | |
| 1y | -1.54% |
| Open | 6.80 | Prev Close | 6.76 | Low | 6.76 | High | 7.09 | Mkt Cap | 746.48M |
| Vol | 76.63K | Avg Vol | 105.93K | EPS | -0.25 | P/E | N/A | Forward P/E | 25.22 |
| Beta | 1.89 | Short Ratio | 21.22 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.82 | 200-d Avg | 7.07 | 1yr Est | 0.00 |
GYRE News
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the anal
Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASD
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analys
Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (NASDAQ:GYRE), a San Diego-based innovative comm
Gyre Therapeutics (NASDAQ:GYRE) sees FY2026 sales of $100.500 million-$111.000 million vs $146.133 m
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.05 per share which missed the anal
Gyre Therapeutics, Inc. (Gyre or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biophar
Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existin
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analys
A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-co
Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical
Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rat
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billi
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Gyre Therapeutics (NASDAQ:GY
Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 2
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly sales of $22.06 million which missed the analyst
Gyre Therapeutics (NASDAQ:GYRE) reported $22.06 million in sales this quarter. This is a 18.82 perce
Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology comp
Full Year 2025 Financial GuidanceFor the full year 2025, the Company expects to generate revenues of
Gyre Therapeutics (NASDAQ:GYRE) reported $27.87 million in sales this quarter. This is a 2.67 percen
As of September 30, 2024, Gyre had cash and cash equivalents of $15.9 million. Based on current plan
Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotech
Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology c
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share. This is unchanged fr
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-th
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enl